Marie Lordkipanidze

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1157803/publications.pdf

Version: 2024-02-01

218381 182168 3,024 107 26 51 citations h-index g-index papers 110 110 110 3544 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. European Heart Journal, 2007, 28, 1702-1708.	1.0	465
2	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology, 2018, 34, 214-233.	0.8	181
3	The role of platelets in the recruitment of leukocytes during vascular disease. Platelets, 2015, 26, 507-520.	1.1	146
4	Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. European Heart Journal, 2008, 29, 2877-2885.	1.0	133
5	Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. Haematologica, 2016, 101, 1170-1179.	1.7	119
6	Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. Blood, 2013, 122, 4090-4093.	0.6	108
7	Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. Journal of Thrombosis and Haemostasis, 2013, 11, 1663-1668.	1.9	103
8	Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. Blood, 2012, 120, 5041-5049.	0.6	92
9	Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence., 2009, 123, 178-186.		75
10	SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects. Journal of Clinical Investigation, 2015, 125, 3600-3605.	3.9	71
11	Response to aspirin in healthy individuals. Thrombosis and Haemostasis, 2009, 102, 404-411.	1.8	66
12	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	1.9	64
13	Use of nextâ€generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders. Journal of Thrombosis and Haemostasis, 2015, 13, 643-650.	1.9	63
14	Genotyping and phenotyping of platelet function disorders. Journal of Thrombosis and Haemostasis, 2013, 11, 351-363.	1.9	62
15	Platelet Function in Aging. Frontiers in Cardiovascular Medicine, 2019, 6, 109.	1.1	61
16	Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. Blood, 2014, 123, e11-e22.	0.6	60
17	Platelet Function Tests. Seminars in Thrombosis and Hemostasis, 2016, 42, 258-267.	1.5	57
18	Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 753-770.	0.4	53

#	Article	IF	Citations
19	Testing Platelet Function. Hematology/Oncology Clinics of North America, 2013, 27, 411-441.	0.9	52
20	50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams. Platelets, 2012, 23, 415-422.	1.1	40
21	Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders. Journal of Thrombosis and Haemostasis, 2014, 12, 660-665.	1.9	40
22	A novel mutation in the P2Y12 receptor and a functionâ€reducing polymorphism in proteaseâ€activated receptorÂ1 in a patient with chronic bleeding. Journal of Thrombosis and Haemostasis, 2014, 12, 716-725.	1.9	40
23	Aspirin resistance: Truth or dare. , 2006, 112, 733-743.		39
24	Assessment of VerifyNow P2Y12 Assay Accuracy in Evaluating Clopidogrel-Induced Platelet Inhibition. Therapeutic Drug Monitoring, 2008, 30, 372-378.	1.0	36
25	Advances in monitoring of aspirin therapy. Platelets, 2012, 23, 526-536.	1.1	35
26	Genetic determinants of response to aspirin: Appraisal of 4 candidate genes. Thrombosis Research, 2011, 128, 47-53.	0.8	32
27	Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. International Journal of Cardiology, 2011, 150, 39-44.	0.8	31
28	Advances in Platelet Function Testing—Light Transmission Aggregometry and Beyond. Journal of Clinical Medicine, 2020, 9, 2636.	1.0	31
29	Platelets Selectively Regulate the Release of BDNF, But Not That of Its Precursor Protein, proBDNF. Frontiers in Immunology, 2020, 11, 575607.	2.2	31
30	Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. Journal of Thrombosis and Haemostasis, 2013 , 11 , $1627-1639$.	1.9	28
31	Mice Lacking the Inhibitory Collagen Receptor LAIR-1 Exhibit a Mild Thrombocytosis and Hyperactive Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 823-835.	1.1	28
32	Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: Identification of the second HPS7 mutation in a patient presenting late in life. Thrombosis and Haemostasis, 2013, 109, 766-768.	1.8	22
33	The prognostic utility of tests of platelet function for the detection of †aspirin resistance†in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-366.	1.3	22
34	Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. International Journal of Cardiology, 2010, 143, 43-50.	0.8	21
35	Platelet Turnover in Atherothrombotic Disease. Current Pharmaceutical Design, 2012, 18, 5328-5343.	0.9	20
36	Aspirin twice a day keeps new COX-1 at bay. Journal of Thrombosis and Haemostasis, 2012, 10, 1217-1219.	1.9	20

#	Article	IF	CITATIONS
37	Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 3193-3202.	1.9	20
38	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. International Journal of Molecular Sciences, 2021, 22, 13079.	1.8	20
39	A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction. Thrombosis and Haemostasis, 2014, 112, 923-932.	1.8	19
40	Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease. Systematic Reviews, 2014, 3, 140.	2.5	19
41	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	1.9	19
42	Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard―light transmission aggregometry. Thrombosis Research, 2009, 124, 418-422.	0.8	17
43	Differential correlation of serum BDNF and microRNA content in rats with rapid or late onset of heavy alcohol use. Addiction Biology, 2021, 26, e12890.	1.4	17
44	Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thrombosis Research, 2009, 124, 546-553.	0.8	16
45	Diversity and impact of rare variants in genes encoding the platelet G protein-coupled receptors. Thrombosis and Haemostasis, 2015, 113, 826-837.	1.8	15
46	Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y ₁₂ receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 543-553.	0.4	15
47	Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease. American Journal of Cardiology, 2009, 104, 1189-1193.	0.7	14
48	Platelet Function in Viral Immunity and SARS-CoV-2 Infection. Seminars in Thrombosis and Hemostasis, 2021, 47, 419-426.	1.5	14
49	The brain-derived neurotrophic factor prompts platelet aggregation and secretion. Blood Advances, 2021, 5, 3568-3580.	2.5	14
50	Why an aspirin a day no longer keeps the doctor away …. Thrombosis and Haemostasis, 2011, 105, 209-210.	1.8	13
51	The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. Clinical Pharmacology and Therapeutics, 2016, 100, 500-512.	2.3	13
52	Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. Thrombosis Research, 2017, 149, 64-69.	0.8	12
53	Increased platelet reactivity and platelet–leukocyte aggregation after elective coronary bypass surgery. Platelets, 2019, 30, 975-981.	1.1	12
54	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. Canadian Journal of Cardiology, 2020, 36, 1298-1307.	0.8	12

#	Article	IF	CITATIONS
55	Antiplatelet Therapy for Atherothrombotic Disease in 2022â€"From Population to Patient-Centered Approaches. Frontiers in Cardiovascular Medicine, 2022, 9, 805525.	1.1	12
56	Differences in plateletâ€rich plasma composition influence bone healing. Journal of Clinical Periodontology, 2021, 48, 1613-1623.	2.3	11
57	Beware of being caught on the rebound. Journal of Thrombosis and Haemostasis, 2011, 9, 21-23.	1.9	9
58	Clinical Tests of Platelet Function. , 2013, , 519-545.		9
59	Severity of Megakaryocyte-Driven Osteosclerosis in Mpig6b-Deficient Mice Is Sex-Linked. Journal of Bone and Mineral Research, 2020, 36, 803-813.	3.1	9
60	Brain-Derived Neurotrophic Factor Mitigates the Association Between Platelet Dysfunction and Cognitive Impairment. Frontiers in Cardiovascular Medicine, 2021, 8, 739045.	1.1	9
61	G6f-Like Is an ITAM-Containing Collagen Receptor in Thrombocytes. PLoS ONE, 2012, 7, e52622.	1.1	9
62	Platelet function testing as a biomarker for efficacy of antiplatelet drugs. Biomarkers in Medicine, 2016, 10, 903-918.	0.6	8
63	Personalizing antiplatelet therapies: What have we learned from recent trials?. Platelets, 2018, 29, 131-139.	1.1	8
64	Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model. Biomolecules, 2020, 10, 1318.	1.8	8
65	Weekâ€Long Highâ€Maintenance Dose Clopidogrel Regimen Achieves Better Platelet Aggregation Inhibition than a Standard Loading Dose before Percutaneous Coronary Intervention: Results of a Doubleâ€Blind, Randomized Clinical Trial. Journal of Interventional Cardiology, 2009, 22, 368-377.	0.5	7
66	Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. Systematic Reviews, 2015, 4, 88.	2.5	7
67	Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease. Platelets, 2015, 26, 545-551.	1.1	7
68	Simultaneous measurement of ATP release and LTA does not potentiate platelet aggregation to epinephrine. Thrombosis and Haemostasis, 2013, 110, 199-201.	1.8	6
69	Tissue-Specificity of Antibodies Raised Against TrkB and p75NTR Receptors; Implications for Platelets as Models of Neurodegenerative Diseases. Frontiers in Immunology, 2021, 12, 606861.	2.2	6
70	Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2022, 20, 2127-2135.	1.9	6
71	Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease. Systematic Reviews, 2013, 2, 16.	2.5	5
72	Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. Thrombosis and Haemostasis, 2016, 115, 905-910.	1.8	5

#	Article	IF	CITATIONS
73	Platelet count and disease – editorial policy. Platelets, 2020, 31, 969-970.	1.1	5
74	Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP study. Thrombosis Research, 2019, 174, 48-50.	0.8	4
75	The effect of aging on the bone healing properties of blood plasma. Injury, 2021, 52, 1697-1708.	0.7	4
76	Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison. Platelets, 2022, 33, 298-303.	1.1	3
77	Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada. CJC Open, 2021, 3, 814-821.	0.7	3
78	Rare missense variants in Tropomyosinâ€4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding. Journal of Thrombosis and Haemostasis, 2022, 20, 478-485.	1.9	3
79	A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMED-F1 study. Supportive Care in Cancer, 2022, 30, 3389-3399.	1.0	3
80	Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities. Thrombosis and Haemostasis, 2022, 122, 1443-1453.	1.8	3
81	Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial. Journal of Thoracic Disease, 2017, 9, E440-E443.	0.6	2
82	Head-to-Head Comparison of Consensus-Recommended Platelet Function Tests to Assess P2Y12 Inhibitionâ€"Insights for Multi-Center Trials. Journal of Clinical Medicine, 2020, 9, 332.	1.0	2
83	Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in nonâ€hypertensive Alzheimer's patients. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12184.	1.8	2
84	Platelet Quiescence in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Bypass Graft Surgery. Journal of the American Heart Association, 2021, 10, e016602.	1.6	2
85	Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel. Cell Reports Medicine, 2021, 2, 100299.	3.3	2
86	A Meta-Analysis of the Effect of Paper Versus Digital Reading on Reading Comprehension in Health Professional Education. American Journal of Pharmaceutical Education, 2021, 85, 8525.	0.7	2
87	Platelet Function Tests., 2017,, 559-570.		2
88	Editorial: Established and Novel Roles of Platelets in Health and Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 835615.	1.1	2
89	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. Frontiers in Pharmacology, 2022, 13, 878416.	1.6	2
90	Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic: reply. European Heart Journal, 2007, 29, 138-139.	1.0	1

#	Article	IF	CITATIONS
91	OC-13 Investigation of underlying platelet function defects in patients with unexplained menorrhagia. Thrombosis Research, 2013, 131, S74.	0.8	1
92	Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?. Thrombosis Research, 2015, 136, 1057-1058.	0.8	1
93	An interview with Professor Gus Born. Platelets, 2018, 29, 744-748.	1.1	1
94	Clinical Tests of Platelet Function. , 2019, , 593-608.		1
95	Clinical importance of thrombocytopenia in patients with acute coronary syndromes: a systematic review and meta-analysis. Platelets, 2019, 30, 817-827.	1.1	1
96	Effects of reading media on reading comprehension in health professional education: a systematic review protocol. JBI Evidence Synthesis, 2020, 18, 2633-2639.	0.6	1
97	Clinical Correlates Identify ProBDNF and Thrombo-Inflammatory Markers as Key Predictors of Circulating p75NTR Extracellular Domain Levels in Older Adults. Frontiers in Aging Neuroscience, 2022, 14, 821865.	1.7	1
98	Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study $\hat{a} \in \hat{a}$ a cross-sectional study. BMJ Open, 2022, 12, e055454.	0.8	1
99	ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON THE USE OF TICAGRELOR VERSUS CLOPIDOGREL PRIOR TO SURGERY. Canadian Journal of Cardiology, 2016, 32, S118-S119.	0.8	0
100	ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON TIMING OF DISCONTINUATION OF TICAGRELOR AND CLOPIDOGREL PRIOR TO SURGERY. Canadian Journal of Cardiology, 2016, 32, S252.	0.8	0
101	Platelets at the heart of therapy. Platelets, 2018, 29, 103-104.	1.1	0
102	ASSOCIATION OF PLATELET ACTIVITY WITH CIRCULATING LEVELS OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) AND COGNITIVE FUNCTION: A CROSS-SECTIONAL STUDY. Canadian Journal of Cardiology, 2019, 35, S122.	0.8	0
103	EFFECT OF LOSARTAN ON PLATELET RESPONSES TO CLASSIC AGONISTS. Canadian Journal of Cardiology, 2019, 35, S26.	0.8	0
104	LARGE-SCALE ASSESSMENT OF PLATELET DIFFERENTIAL SECRETION. Canadian Journal of Cardiology, 2019, 35, S127-S128.	0.8	0
105	750. Critical Care Medicine, 2019, 47, 354.	0.4	O
106	A randomized double-blind pilot study comparing cetirizine with diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions Journal of Clinical Oncology, 2021, 39, e24080-e24080.	0.8	0
107	Normal Response to Aspirin in Healthy Individuals: Cross-Comparison of Light Transmission Aggregometry, VerifyNowâ,,¢ System, Platelet Count Drop, Thrombelastography (TEG®) and Urinary 11-dehydrothromboxane B2 Blood, 2007, 110, 934-934.	0.6	0